30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

MIACH Orthopaedics Secures $22.5 Million to Support ACL Implant -


MIACH Orthopaedics closed a US $22.5MM round of Series A financing. Funds will support accelerated manufacturing and continued clinical trials for the company’s first implant, Bridge-Enhanced® ACL Repair (BEAR®), designed to stimulate healing of torn anterior cruciate ligaments (ACL). The round was co-led by Amzak Health Investors LLC and DSM Venturing, with participation from the NFL Players Association and additional investors. BEAR technology is a proprietary, bio-engineered sponge used as a bridging scaffold to stimulate healing of a torn ACL. Unlike traditional ACL reconstruction, the BEAR procedure does not require taking grafts from healthy parts of the leg.   

Preclinical studies, according to MIACH, suggest that knees treated with BEAR have a significantly lower rate of arthritis than those treated with traditional ACL reconstruction. The company has initiated an IDE clinical trial using ~100 human patients. (MIACH Orthopaedics, 9/17/18)